Bone and Mineral Metabolism Disorders News

A study of provider prescribing patterns revealed patients with advanced chronic kidney disease, especially those on dialysis, had lower rates of osteoporosis treatment than patients with earlier stages of kidney disease.

A meta-analysis of randomized controlled trials suggested magnesium supplementation alone might benefit patients on hemodialysis with chronic kidney disease-mineral bone disorder.

Older men with a skeletal mass index threshold below 42 cm2 per m2 experienced more hospitalizations with longer stays in the year following kidney transplantation than those who had a higher preoperative skeletal mass index.

While all the assessed instruments demonstrated a high prevalence of frailty in patients receiving hemodialysis, researchers from the United Kingdom found a 21.5% difference in frailty prevalence between the lowest and highest estimations.

A study of patients receiving hemodialysis in Japan demonstrated the efficacy of tenapanor for treating hyperphosphatemia with fewer daily pills required in a 26-week period.

Investigators found a “relatively high” prevalence of pre-dialysis hyperkalemia among patients on hemodialysis, with women, younger patients and Hispanic individuals showing higher rates of the condition, according to findings.

For patients with advanced chronic kidney disease, the prevalence of frailty varied widely based on the tool used for assessment, according to a study conducted in Canada.

Patients aged 75 years and older with chronic kidney disease, type 2 diabetes, hypertension and hyperkalemia had “significant reductions in serum potassium” after treatment with patiromer, according to results of a secondary analysis.

Defining hypothyroidism by thyroid-stimulating hormone level, researchers found the condition was more common in patients with worsening levels of kidney function (as determined by eGFR slope), as well as in those who had proteinuria.

For patients with advanced chronic kidney disease, low serum zinc concentration was linked to an increased likelihood of hospitalizations due to infections. This elevated risk was especially high for individuals on proton pump inhibitors.